Authors: Lhomme, C Vermorken, JB Mickiewicz, E Chevalier, B Alvarez, A Mendiola, C Pawinski, A Lentz, MA Pecorelli, S

Citation: C. Lhomme et al., Phase II trial of vinorelbine in patients with advanced and/or recurrent cervical carcinoma: an EORTC Gynaecological Cancer Cooperative Group Study, EUR J CANC, 36(2), 2000, pp. 194-199

Authors: Vermorken, JB Kobierska, A Chevallier, B Zanaboni, F Pawinski, A Bolis, G

Citation: Jb. Vermorken et al., A phase II study of high-dose epirubicin in ovarian cancer patients previously treated with cisplatin, ANN ONCOL, 11(8), 2000, pp. 1035-1040

Authors: Pawinski, A Crowther, D Keizer, HJ Voute, PA Somers, R van Glabbeke, M Lentz, MA van Oosterom, AT

Citation: A. Pawinski et al., The EORTC phase II study of iproplatin in advanced osteogenic sarcoma, EUR J CANC, 35(1), 1999, pp. 163-164

Authors: Wynendaele, W Derua, R Hoylaerts, MF Pawinski, A Waelkens, E de Bruijn, EA Paridaens, R Merlevede, W van Oosterom, AT

Citation: W. Wynendaele et al., Vascular endothelial growth factor measured in platelet poor plasma allowsoptimal separation between cancer patients and volunteers: A key to study an angiogenic marker in vivo?, ANN ONCOL, 10(8), 1999, pp. 965-971

Authors: Pawinski, A Tumolo, S Hoesel, G Cervantes, A van Oosterom, AT Boes, GH Pecorelli, S

Citation: A. Pawinski et al., Cyclophosphamide or ifosfamide in patients with advanced and/or recurrent endometrial carcinoma: a randomized phase II study of the EORTC Gynecological Cancer Cooperative Group, EUR J OB GY, 86(2), 1999, pp. 179-183

Authors: Wynendaele, W van Oosterom, AT Pawinski, A de Bruijn, EA Maes, RA

Citation: W. Wynendaele et al., Angiogenesis: possibilities for therapeutic interventions, PHARM WORLD, 20(6), 1998, pp. 225-235